web analytics
23.7 C
Munich
Wednesday, June 29, 2022

The Exciting Story of AngioSoma Inc (OTCMKTS: SOAN)

AngioSoma Inc (OTCMKTS: SOAN) is heating up after the Company announced its subsidiary SomaCeuticals, Inc., has executed a licensing agreement with 7 to Stand, Inc. or the exclusive global rights to U.S. patent 10,610,592 issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020 for treatment of Multiple Sclerosis. MS is ranked eighth by drug invoice spending among the top therapeutic classes in the U.S. in 2016, representing nearly $19 billion in drug spending alone. SOAN CEO Alexanderia Blankenship stated:  “I am delighted to be working with 7 to Stand, Inc. to begin working with the FDA. The unofficial trial results from Italy are quite encouraging, and we look forward to engaging with the FDA in the near future.”

SOAN recently elected James C. Katzaroff as President of its subsidiary SomaCeuticals, Inc., and is getting noticed fast by penny stock speculators who see the current action as the start of big things to come for AngioSoma.

AngioSoma Inc (OTCMKTS: SOAN) is a wellness company dedicated to bringing innovative, effective and high-quality supplement products to the medical, wellness and adult-use markets through its marketing subsidiary, SomaCeuticalsTM. SomaCeuticals has acquired a diversified supply of supplements, strong clinical, scientific and operating capabilities and leading product research and development infrastructure in order to create trusted products and brands in an expanding global market. In May the Company reported it was focusing among other things on development and commercialization of its coating for metal stents.

The Company operates the website muscles4u.com focused on marketing its products & supplements developed by scientists through years of research under its SomaCeuticals, Inc. brand. The Companies supplements cover three core segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.

AngiSoma subsidiary SomaCeuticals, Inc., recently elected James C. Katzaroff as President to serve until his successor is elected and qualified. Mr. Katzaroff is the founder of Advanced Medical Isotope Corp. (now known as Radiogel) and was the Chairman and Chief Executive Officer from 2007 through December 2016.  Since December 2016 to present, Mr. Katzaroff is Senior Managing Director at KATMO, LLC. Mr. Katzaroff is highly regarded internationally for his proven expertise in corporate organization as well as developing and implementing impactful senior-level corporate strategy.

To Find out the inside Scoop on SOAN  Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

SOAN

On August 24 SOAN announced its subsidiary SomaCeuticals, Inc., has executed a licensing agreement with 7 to Stand, Inc. or the exclusive global rights to U.S. patent 10,610,592 issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020 for treatment of Multiple Sclerosis (MS).

Multiple Sclerosis (MS) is a chronic disease in which the immune system of the individual attacks the central nervous system and affects the nerve cells. There is no known cure using current treatments and is the most common immune-mediated disorder affecting the central nervous system. With over 2.3 million people affected and with each individual spending approximately $70,000 per year, MS ranked eighth by drug invoice spending among the top therapeutic classes in the U.S. in 2016, representing nearly $19 billion in drug spending alone.

SOAN CEO Alexanderia Blankenship stated:  “I am delighted to be working with 7 to Stand, Inc. to begin working with the FDA. The unofficial trial results from Italy are quite encouraging, and we look forward to engaging with the FDA in the near future.”

Fabrizio de Silvestri said: “My patented formula is a composition for treating neurodegeneration, including an antibiotic, an antifungal agent, and a lipophilic potentiating agent in synergistically effective amounts. I have seen our preliminary results and stand unequivocally encouraged to bring this to the people who are suffering from this chronic disease — of which I am one of the subjects who took part in the unofficial Italian trials. I can hardly contain my enthusiasm as we move towards our interaction with the FDA.”

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $2.8 million market valuation SOAN has $50k in the treasury and very little debt on the books. The Company is fully reporting and has a pink current designation from OtcMarkets Group. SOAN is heating up after the Company announced its subsidiary SomaCeuticals, Inc., has executed a licensing agreement with 7 to Stand, Inc. or the exclusive global rights to U.S. patent 10,610,592 issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020 for treatment of Multiple Sclerosis. MS is ranked eighth by drug invoice spending among the top therapeutic classes in the U.S. in 2016, representing nearly $19 billion in drug spending alone. SOAN CEO Alexanderia Blankenship stated:  “I am delighted to be working with 7 to Stand, Inc. to begin working with the FDA. The unofficial trial results from Italy are quite encouraging, and we look forward to engaging with the FDA in the near future.” The stock is on the move and has quickly attracted a fast growing shareholder base including some old time penny stock speculators that know what they are doing. We will be updating on SOAN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with SOAN.

WAIT! Do You Want Stocks That Could Go Up 348% In Days Delivered To Your Inbox For FREE?

Disclosure: we hold no position in SOAN either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.